Anjali T Owens MD
Adult Congenital Heart Disease, Cardiac Electrophysiology, Heart Failure & Transplantation, Interventional Cardiology
Assistant Professor, Medicine, Perelman School of Medicine
Join to View Full Profile
3400 Spruce StPhiladelphia, PA 19104
Phone+1 215-314-0343
Dr. Owens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Cardiovascular Disease, 2010 - 2011- University of Pennsylvania Health SystemFellowship, Cardiovascular Disease, 2007 - 2010
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2003 - 2006
Duke University School of MedicineClass of 2003, B.A.
Certifications & Licensure
PA State Medical License 2003 - 2026
American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy
- DCM Precision Medicine Study Start of enrollment: 2016 Jun 07
Publications & Presentations
PubMed
- Long-term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights from VALOR-HCM Trial.Milind Y Desai, Anjali Owens, Sara Saberi, Andrew Wang, Kathy Wolski
Circulation. Genomic and Precision Medicine. 2025-03-31 - Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study.Javier Jimenez, Hanyu Ni, Stuart D Katz, Garrie J Haas, Jinwen Cao
Circulation. Genomic and Precision Medicine. 2025-03-28 - Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy.Joshua K Meisner, Aaron Renberg, Eric D Smith, Yao-Chang Tsan, Brynn Elder
Circulation. 2025-03-18
Journal Articles
- Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical PracticeMuthiah Vaduganathan, Javed Butler, Paul A Heidenreich, Michelle M Kittleson, Anjali Tiku Owens, Pamela N Peterson, Clyde W Yancy, Gregg C Fonarow, JAMA Cardiology
Authored Content
- Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to KnowFebruary 2020
- Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to KnowFebruary 2020
Press Mentions
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific SessionsSeptember 27th, 2024- U.S. Food and Drug Administration Approves Camzyos™ (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and SymptomsApril 29th, 2022
- FDA Approves Mavacamten, First Treatment for Obstructive Hypertrophic CardiomyopathyApril 29th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
